August 5, 2013 — Thubrikar Aortic Valve’s Optimum TAV, transcatheter aortic valve implantation (TAVI) system, has surpassed 200 million cycles in an ongoing durability test — which simulates over five years in humans and meets the requirement set by the International Organization for Standardization (ISO) — in a third party GLP study.
The company previously demonstrated feasibility of its Optimum TAV and delivery catheters in eight acute and chronic sheep. It has filed patents for its Optimum TAV and catheters, and has accomplished all of these milestones within $1 million.
The Optimum TAV is a low-profile, bovine pericardial, self-expanding percutaneous valve that is a heart valve treatment option for aortic stenosis. Optimum TAV was designed to mimic the natural aortic valve, improve durability and to be used in valve-in-valve procedures and bicuspid patients.
For more information: gust.com/c/thubrikar_aortic_valve
July 02, 2026 
